Abstract
BackgroundChemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is a new standard of care for inoperable stage III NSCLC. The present study aims to evaluate the oncological...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have